Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Network San Marino.
July 2025
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | |
7 | 8 | 9 | 10 | 11 | 12 | 13 |
14 | 15 | 16 | 17 | 18 | 19 | 20 |
21 | 22 | 23 | 24 | 25 | 26 | 27 |
28 | 29 | 30 | 31 |
August 2025
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1 | 2 | 3 | ||||
4 | 5 | 6 | 7 | 8 | 9 | 10 |
11 | 12 | 13 | 14 | 15 | 16 | 17 |
18 | 19 | 20 | 21 | 22 | 23 | 24 |
25 | 26 | 27 | 28 | 29 | 30 | 31 |
September 2025
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 |
8 | 9 | 10 | 11 | 12 | 13 | 14 |
15 | 16 | 17 | 18 | 19 | 20 | 21 |
22 | 23 | 24 | 25 | 26 | 27 | 28 |
29 | 30 |
Press releases published on August 31, 2025

Anavar For Women And Men: CrazyBulk Launch Anavar Legal Steroid Alternative For Female Read Dosage, Side Effects, (Before and After Cycle results)
New York, Aug. 31, 2025 (GLOBE NEWSWIRE) -- August 31, 2025 | New York CrazyBulk proudly announces the release of Anavar (Anvarol), its legal and safe alternative to the anabolic steroid Anavar. Designed for cutting cycles, Anvarol helps users shred fat …

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology New Analysis Shows Annual Incidence Rate of Atrial Fibrillation …

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically significant reductions in secondary …

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No Approved Therapeutics Genotypic Status …

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted in vitro data assessing the effects of EPA on lipoprotein(a) [Lp(a)] oxidation and on cellular stress and inflammatory protein …